263,644 Shares in 2seventy bio, Inc. (NASDAQ:TSVT) Acquired by Monimus Capital Management LP

Monimus Capital Management LP bought a new stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 263,644 shares of the company's stock, valued at approximately $775,000. Monimus Capital Management LP owned about 0.51% of 2seventy bio at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in TSVT. Erste Asset Management GmbH acquired a new position in shares of 2seventy bio in the 3rd quarter worth $25,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of 2seventy bio in the fourth quarter worth approximately $32,000. Raymond James Financial Inc. acquired a new stake in shares of 2seventy bio during the fourth quarter valued at approximately $52,000. Readystate Asset Management LP acquired a new position in 2seventy bio in the 3rd quarter worth approximately $53,000. Finally, GSA Capital Partners LLP acquired a new stake in 2seventy bio during the 3rd quarter valued at $64,000. 93.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total transaction of $25,350,607.23. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 7.20% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

TSVT has been the topic of several recent analyst reports. Leerink Partners reissued a "market perform" rating and set a $5.00 price target (down from $9.00) on shares of 2seventy bio in a research report on Tuesday, March 11th. Morgan Stanley dropped their price objective on shares of 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Friday, March 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of 2seventy bio in a research note on Friday, March 7th. Finally, Leerink Partnrs downgraded shares of 2seventy bio from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $6.67.

2seventy bio Stock Performance

TSVT remained flat at $4.96 on Wednesday. The company had a trading volume of 468,446 shares, compared to its average volume of 620,134. 2seventy bio, Inc. has a 12-month low of $2.29 and a 12-month high of $5.99. The stock's fifty day simple moving average is $2.85 and its two-hundred day simple moving average is $3.69. The company has a market capitalization of $255.88 million, a PE ratio of -2.67 and a beta of 1.73.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.